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Temozolomide in the treatment of malignant brain tumors in children
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M a t e r i a l  a n d  m e t h o d s .  A  new alkylating cytostatic drug -  Temozolomide (Temodal) -  was administered to 13 children 
treated for malignant brain tumors between June 1999 and June 2002. The patients were followed up till November 2002. In 
two cases Temozolomide was employed preoperatively as the first-order agent aiming to reduce the tumor mass, while 
11 patients received Temozolomide following the failure o f previous standard therapy.
Resul t s .  Complete and almost complete regression was achieved in 2 cases. A  short-term regression or stabilization o f tumor 
size lasting 2-12 months was noted in 3 children. Five patients showed no therapeutic effect and further tumor progression 
occurred. In two patients the therapy was discontinued. In preoperative patients Temozolomide was successful in one patient. 
C o n c l u s i o n s .  Temozolomide was successful in 3 patients while in 3 children the disease stabilized for a period o f 2-12 
months.
Temozolomide w leczeniu złośliwych guzów mózgu u dzieci
M a t e r i a ł  i m e to d y .  U 13 dzieci leczonych z  powodu złośliwych guzów mózgu w okresie od czerwca 1999 r. do czerwca 
2002 r. zastosowano nowy cytostatyk, alkilujący temozolomide (Temodal). Kontrolę pacjentów po leczeniu prowadzono do 
listopada 2002 r. W  dwóch przypadkach temozolomide zastosowano przedoperacyjnie, celem zmniejszenia masy guza, 
podczas gdy 11 pacjentów otrzymało temozolomide z  powodu niepowodzenia standardowej terapii.
Wynik i .  Całkowitą i prawie całkowitą regresję otrzymano w 2 przypadkach. Krótkotrwałą regresję lub stabilizację masy guza, 
trwającą od 2 do 12 miesięcy, odnotowano u 3 dzieci. U 5 dzieci nie wykazano terapeutycznego efektu i wystąpiła progresja 
choroby. U 2 pacjentów leczenie przerwano. U pacjentów, u których Temozolomide zastosowano przedoperacyjnie, lek 
okazał się skuteczny u jednego.
W n i o s k i .  Temozolomide wydaje się być skuteczny u 3 leczonych pacjentów. U 3 dzieci stabilizacja choroby utrzymała się 
przez okres 2-12 miesięcy.
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Introduction
Temozolomide (Temodal) is a new alkylating cytostatic 
agent, that has found its use in managing recurrent 
malignant brain gliomas, predominantly in adult patients 
[1-12]. The drug is administered orally as tablets at the 
dose of 150-200 mg/m2/day over 5 days. The cycles are 
repeated every 28 days. Temozolomide is rapidly absorbed 
when administered orally and is spontaneously hydrolyzed 
at physiologic pH  to its active m etabolite 3-methyl- 
(triazen-1-yl) imidazole-4-carboximide (M TIC). The 
mechanism of action of MTIC is thought to be alkylation 
of the 06 position of guanine with additional alkylation 
at the N7 position. In preclinical studies, temozolomide 
has been shown to exert significant antitum or activity
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against a variety of human central nervous system tumor 
xenograft models [2-3, 5, 7, 9]. No accumulation occurs 
with multiple daily dosing. temozolomide achieves higher 
levels in human astrocytoma, as compared to the contrala­
teral normal brain [3]. In clinical studies temozolomide 
has been shown to have 100% oral bioavailability and 
extensive tissue distribution including penetration of the 
blood-brain barrier [2-5, 7-12]. Dose-limiting toxicity 
appears as myelosuppression, consisting of grade 3 or 4 
throm bocytopenia and/or neutropenia. Platelet and 
neutrophil count nadirs occur late in the cycle (usually 
between days 21 and 28) and recovery is rapid within 1-2 
weeks. Temozolomide is reported to cause a relatively 
small num ber of adverse effects, mainly in the form 
of decreased blood count index [2-5, 8, 9, 12]. In 
a randomized multicenter phase II study temozolomide 
vs. Procarbazine, 42% adult patients suffered nausea, 
35% vomiting and 30% fatigue [4]. These side effects are 
similar to other reports [3, 5, 11]. Reports indicate that 
temozolomide has been employed in children in a few
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centers and only fewer than 100 patients worldwide have 
received the drug, not only in relapsed brain gliomas, but 
also in medulloblastomas and PNET tumors [13, 18].
Material and methods
Temozolomide therapy was comm enced at the University 
Children's H ospital of Cracow in June 1999. The treatm ent 
program included 13 patients (7 girls and 6 boys) aged 3-19 
years (mean age 10.6 years). In cases ofpineoblastoma specimens 
for histopathology were obtained by a stereotactic biopsy, while 
in the remaining patients specimens were collected intraoperati- 
vely, during open neurosurgical procedures. Table I presents 
the patients and their histopathological diagnoses.
Table I. Histopathological findings in children with brain tumors
Histopathology No. of patients
Medulloblastoma 3
Pineoblastoma 1
Glioblastoma multiforme 3
Anaplastic astrocytoma 3
Fibrillary astrocytoma with single cellular atypia foci 2
Brainstem glioma 1
Temozolomide was administered orally every 28 days for 5 
days at the dose of 150-200 mg/m2, depending on blood cell 
count values and previous chemotherapy. In the group with no 
effect after standard treatm ent (2 children) or with relapsed 
disease (9 patients) no more than 6 cycles were given. In the 
group with preoperative chemotherapy (2 children), 3 courses of 
chemotherapy were prescribed. In the case of progression of 
the disease the treatm ent was discontinued.
P a t i e n t s
Medulloblastoma
Temozolomide was employed in 3 children: a 9-year old boy 
treated 6 months earlier because of his T2M1 disease according 
to Chang, a 6-year old girl with a T3AM1 tum or and a 10-year 
old boy with advanced T3AM1 disease. All the children had 
been previously subjected to chem otherapy and total CNS 
irradiation therapy with an increased dose applied to the tumor 
site. The patients relapsed within 6 months to 4 years after the 
completion of treatm ent. All the children had disseminated 
disease. They presented with severe pain involving the 
lumbosacral segment of the spine.
Pineoblastoma
A  15-year old girl with pineoblastoma: one year after the comple­
tion of chem otherapy and irradiation therapy, CT and M RI 
revealed persistent residual tum or mass.
M a l i g n a n t  b r a i n  g l i o m a s
Relapses at the tumor site were detected in 5 children. No total 
regression after standard treatment was observed in two patients. 
Two (a 14-year old girl and a boy) had grade III (W HO) 
malignant astrocytomas. Both patients had been previously 
treated surgically and subjected to irradiation therapy. The girl 
manifested tum or regrowth at the original site one year after 
radiotherapy completion. The patient was reoperated  and
according to the operator the tum or mass was completely 
resected. The 14-year old boy with a malignant brainstem  
astrocytoma had undergone a non-radical tum or excision and 
subsequently irradiation therapy. Two months after radiotherapy, 
tum or regrowth occurred. The third patient was a 19-year old 
girl with glioblastoma multiforme presented with massive 
tum or regrowth one year after radiotherapy completion. The 
patient was reoperated and according to the operator, macro- 
scopically the mass was completely resected. A nother patient 
was a 10-year old boy treated surgically and irradiated in our 
center due to a grade III (WHO) malignant brain glioma. Seven 
years later tum or regrowth was detected at the tum or site 
and a radical surgery as attested  by the operator followed. 
Intraoperative histopathology revealed a glioblastoma multiforme 
type tumor.
Three children were diagnosed with brainstem  gliomas, 
including two with histologically confirmed brainstem fibrillary 
astrocytomas with isolated atypia foci. These included a 6-year old 
boy previously subjected to chemotherapy and radiotherapy in 
another center and a 14-year old girl treated with irradiation 
therapy alone. Less than one year after treatm ent completion, 
the boy manifested massive tum or regrowth. The patient was 
reoperated and tumor mass situated in the central and superior 
pons was partially resected. In the case of the second patient, 
apart from a brainstem  tum or, she also revealed neoplastic 
cells within the spinal canal. Following irradiation therapy 
involving the entire central nervous system with an increased 
dose applied to the tumor site, the child presented with complete 
regression within the spinal canal and partial regression of 
brainstem mass.
The third patient was a 7-year old boy with diffuse 
brainstem glioma. The tumor was partially resected with residual 
brainstem malignancy after irradiation therapy.
P r e o p e r a t i v e  t e m o z o l o m i d e  a d m i n i s t r a t i o n
The drug was employed in two girls. One of them was a 3-year 
old patient with a CT and MRI-confirmed extensive brainstem 
tum or suggestive of a markedly malignant glioma. The other 
patient was a 12-year old girl with a CT and MRI-confirmed 
malignant brainstem glioma.
Results of temozolomide chemotherapy
In the group of patients in whom standard therapy 
had failed, total and almost total tum or regression 
following temozolomide chem otherapy was achieved 
in two children, namely in a girl with pineoblastoma and 
in another female patient with brainstem  fibrillary 
astrocytoma with cellular atypia. Any evaluation of this 
outcom e is difficult, since post-radiotherapy residual 
lesions may undergo a slow, long-term remission. In seven 
children temozolomide failed to prevent further tumor 
progression. In two patients the therapy was discontinued. 
This group included a boy with diffuse brainstem glioma 
who developed grade IV W HO bone m arrow aplasia 
after the first cycle, and a 19-year old girl with relapsed 
glioblastoma multiforme, who died in a regional hospital 
due to subarachnoid hemorrhage. In the two children in 
whom temozolomide was administered preoperatively, 
a therapeutic effect was achieved in one patient. The girl 
was operated on and intraoperative histopathology 
revealed a glioblastoma multiforme-like malignancy with 
numerous post-chemotherapy necrotic foci. Table II.
Table II. Outcome of temozolomide therapy in children with m alignant brain  tum ors
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Histopathology Sex Age Cause of 
Temodal treatm ent
No of 
Temodal cycles
D uration of 
symptom 
stabilization
Outcome
Glioblastoma multiforme
Anaplastic astrocytoma
Fibrillare astrocytoma 
with cellular atypia
Medulloblastoma
Brainstem glioma
Fibrillare astrocytoma 
with cellular atypia
Pineoblastoma
Anaplastic astrocytoma 
Glioblastoma multiforme
F 19 years Tumor relapse
M 10 years
M 14 years
F 14 years
M
M
M
6 years
9 years Tumor relapse
M 10 years
F 6 years
7 years No total tum or regression 
after standard treatm ent
F 14 years
F 15 years
F 12 years Neoadjuvant treatm ent
F 3 years
I
II
II
II
III
IV 
VI
VI
VI
II
III
Symptom-free 
1,5 month
No effect
1 month
No effect
2 months 
6 months
12 months
Symptom-free 
Symptom-free 
No effect
D eath because of 
subarachnoid hemorrhage 
Progression 
D eath
Progression
D eath
Progression
D eath
Progression
D eath
Progression
D eath
Progression
D eath
Progression
D eath
Lost to the study
Regression 
Alive near 3 years
Total regression 
Alive 2,5 years
Progression
Regression of symptoms Tumor shrinkage
II
I
Discussion
Data originating from clinical temozolomide trials suggest 
that the drug evokes a relatively small number of adverse 
effects and is particularly well tolerated by children when 
adm inistered orally [3, 4, 6, 11-18]. Unfortunately, 
communications of temozolomide employed in relapsed 
brain malignancies in children are still scarce, and the 
analyzed groups of patients are small [13-18]. D ata on 
temozolomide therapy originate mostly from adult 
centers. A multicenter, randomized clinical trial carried 
out in large groups of adult patients has demonstrated 
that temozolomide is more effective in treating relapsed 
glioblastoma multiforme than Procarbazine. The 6-month 
overall survival in the temozolomide group was 60%, 
while in the Procarbazine patients the corresponding 
value was 44% only [4]. In his clinical study of 48 adult 
patients with recurrent anaplastic oligodendrogliomas, who 
had been previously trea ted  with irradiation therapy 
and PCV chemotherapy (Procarbazine, Lomustine and 
Vincristine), Chinot employed temozolomide and de­
m onstrated a com plete response in 16.7% patients, 
a partial response in 27.1% and a stable disease in 
39.6% [12]. Also the quality of life improves in patients 
on temozolomide, and the time lapse before disease 
progression occurs is prolonged. This has been demon­
strated by the largest to-date clinical trial carried out in 
525 adult patients with relapsed malignant gliomas [5]. 
O ther clinical studies have pointed to a low therapeutic 
effectiveness of temozolom ide in the treatm ent of 
malignant brain gliomas, but with a clear improvement 
in the quality of life [6, 10, 11].
In the investigated group of 11 children with relapsed 
malignant brain tumors or after standard therapy failures, 
tem ozolom ide seems to be successful in two patients 
(18%). Once again it is difficult to evaluate this outcome, 
since both patients who were administered temozolomide 
had persistent residual tumor mass fragments following 
standard radiotherapy. Possibly the reaction to 
temozolomide therapy is found in a slow tum or mass 
regression following irradiation therapy. A doubtlessly 
positive palliative effect has been achieved in three 
children with medulloblastoma, who dem onstrated 
resolution of such symptoms as headache, nausea, 
vomiting, balance disturbances and severe sacrolumbar 
pain, observed already after the first cycle of therapy. For 
the period of 2-12 months these patients were in a very 
good general state and asymptomatic. The drug inhibited 
the neoplastic process for this time and the patients were 
able to function without any symptoms of the disease. 
O ther patients showed a brief clinical im provement 
following temozolomide therapy, yet the drug did not
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prevent further progress of the disease. Nevertheless, 
aware of the fact that the investigated group of patients 
consisted of individuals without any chances for a cure, we 
believe that the use of temozolomide in order to achieve 
even brief remissions allowing the children to be pain- 
free and capable of normal functioning was justified. No 
temozolomide -associated toxicity was noted in two 
children. Four children showed mild bone marrow toxicity 
of grade II (W HO). Five patients m anifested grade
III bone marrow aplasia (WHO), while one showed grade
IV aplasia and treatm ent was discontinued. A  19-year 
old patient died due to a subarachnoid hem orrhage 
showing no histopathological signs of bone marrow 
aplasia.
Of two children subjected to preoperative 
temozolomide chemotherapy, partial tumor regression 
was achieved in one.
Our results are similar to data from pediatric centers 
where temozolomide was employed in children. Unfor­
tunately, such reports are still too scarce and predo­
minantly of a preliminary character.
Conclusions
-  In view of its oral route of adm inistration, 
temozolom ide is a well tolerated  form of chem o­
therapy in children.
-  In 3 children with medulloblastoma stabilization of the 
disease was achieved, for a period of 2 to 12 months 
and allowed the patients to be pain-free and to 
function normally.
-  The paper sums up the observations of 13 patients. 
The issue of temozolomide effectivness in children 
with malignant brain tumors reguires futher studies in 
a more numerous group of patients.
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